Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001404644-25-000041
Filing Date
2025-05-09
Accepted
2025-05-09 07:19:22
Documents
78
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ngne-20250331.htm   iXBRL 10-Q 1316171
2 EX-10.2 a2025inducementplanformofo.htm EX-10.2 44682
3 EX-31.1 ngne-2025formq110xqxex311p.htm EX-31.1 9560
4 EX-31.2 ngne-2025formq110xqxex312p.htm EX-31.2 9691
5 EX-32.1 ngne-2025formq110xqxex321.htm EX-32.1 7265
11 ngne-20250331_g1.jpg GRAPHIC 68897
12 ngne-20250331_g2.jpg GRAPHIC 93681
  Complete submission text file 0001404644-25-000041.txt   6886022

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20250331.xsd EX-101.SCH 44232
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ngne-20250331_cal.xml EX-101.CAL 54250
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ngne-20250331_def.xml EX-101.DEF 202417
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20250331_lab.xml EX-101.LAB 597987
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20250331_pre.xml EX-101.PRE 414891
81 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20250331_htm.xml XML 741452
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36327 | Film No.: 25928376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)